All Content Clinical Leader

  1. From Protocol To People: Teva's Patient-First Clinical Trials Approach 7/14/2025

    Teva Pharmaceuticals' Head of Global Early Clinical Development Eran Harary, MD, shares how the company approaches drug development by getting patient input early and often.

  2. A Guide To Guidelines: How ICH And Others Help Us Conduct Better Trials 7/11/2025

    Guidelines abound in clinical research. So, how should sponsor companies and partners think about their role in ensuring compliance? Consultant Kamila Novak explores their importance.

  3. Streamline Recruitment With Confidence 7/10/2025

    Transform your clinical trial recruitment with a service that delivers faster, more cost-effective enrollment, particularly for hard-to-reach populations.

  4. Recruiting High-Performing Sites To Beat Forecasted Trial Start Date 7/10/2025

    Explore a partnership that enabled Syneos Health to achieve its enrollment goals, increasing the likelihood of the study's success, and resulting in cost savings and maximized efficiency with minimal delays.

  5. A New Approach To Dynamic Clinical Oversight With Centralized Insights 7/10/2025

    RBQM is transforming clinical trial oversight. By automating protocol digitalization, site selection, and risk assessments 360° Monitoring enables the proactive identification of CtQ factors.

  6. RWD, New Technologies Show Potential In Clinical Trial Recruitment 7/10/2025

    Leveraging RWD transforms feasibility and recruitment from reactive processes into strategic drivers of clinical trial success.

  7. Use Case: How Consulting & Analytics Can Guide Clinical Strategy 7/10/2025

    A large European pharmaceutical company sought to benchmark a CRO’s suggestions involving a Phase III trial for a newly acquired asset.

  8. Sickle Cell Cure Within Reach, But At A Steep Cost 7/10/2025

    Treatment options for sickle cell disease (SCD) and newly available gene therapies represent a potential cure. However, the latter are costly and thus remain out of reach for many SCD patients.

  9. How An Australia-First Strategy Cut 63% From Our R&D Spend 7/10/2025

    Etira CEO Russell Hayward explains how conducting the company's early-stage trials in Australia has yielded big savings, shortened timelines, and produced FDA-ready data.

  10. Part Of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition Of Ajinomoto Althea, Enhancing U.S. Drug Product Manufacturing For Aseptic Filling Of Prefilled Syringes & Cartridges 7/9/2025

    The acquisition furthers recent growth in sterile fill/finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug conjugates.